Superior Extended-release Formulations to Improve Human Health

The Need

Millions of people around the world suffer from chronic diseases and rely on medications that must be taken for years. In addition, the opiate crisis has created a generation of individuals with Opioid Use Disorder, many of whom suffer needlessly when they try to get help because the medications are unavailable or so short-lived that they risk falling back into addiction.

From cancer to schizophrenia and from opioid abuse to depression, Plumb Pharmaceuticals believes it has an answer to help these people in need.

The Innovation

Plumb Pharmaceuticals has developed a platform technology for the development of super-extended-release medications. Our patented Advanced Quantload (AQL) system for producing super-extended-release formulations of weak-base, small molecule drugs, extends release 3-5X longer than current medications. AQL can be used for a wide variety of compounds, including antidepressants, stimulants for treating ADHD, anti-HIV drugs, antibiotics, antipsychotics, cancer chemotherapy agents, antihistamines, and analgesics. This enhanced delivery method is achieved via proprietary lipid nanoparticle technology patented by Plumb.

The Team

Jacqueline Hind, MS


Jackie is a former Vice President and Chief Operating Officer for Swallow Solutions. She is experienced in strategic planning and leadership in healthcare and medical devices.

Timothy Heath, PhD

Co-Founder and Chief Technical Officer

Tim is a lipid particle biochemist with 40+ years in research on lipid nanoparticle carriers. He is the inventor of the Advanced Quantload (AQL)methodology that underpins the formulations being developed by Plumb.

Lisa Krugner-Higby, DVM, PhD

Co-Founder and Chief Scientific Officer

Lisa has 30+ years of clinical expertise and extensive experience in the design and conduct of pre-clinical animal studies. As a boarded laboratory animal veterinarian, she has been working in the field of pain control and in vivo studies of extended-release drug formulations since 1997.

Paul V. Radspinner

Board Representative

Paul brings 25+ years of experience in leadership roles in the pharmaceutical and biotech industries. Most recently he founded FluGen, Inc., a clinical stage vaccine company; raised $30+ million in seed and venture capital and led the company through pre-clinical studies, IND filing, and its first-in-man study.

Current Grant Funding

NIH: 1R43DA04409701A1 and 1R43DA04409701A1S1
SBIR Phase 1: A 3-month Release Naltrexone for Addiction Treatment

NSF 1819943 SBIR Phase 1: Refining a 3-month release buprenorphine,
advancing a drug delivery platform

For Investors


Plumb Pharmaceuticals’ value proposition is based on the idea that super-extended release medications increase patient compliance and reduce healthcare costs. The generalizability of this proprietary platform topotentially hundreds of approved medications including those for pain, infection, HIV, ADHD and depression make this a clinical game changer.

We welcome support as we grow and evolve Plumb Pharmaceuticals’AQL platform technology.
To explore future investment opportunities, contact Jacqueline Hind, President for more information at

Contact Us

    Plumb Pharmaceuticals, LLC

    1202 Ann Street
    Suite 122
    Madison, WI 53713


    (608) 220-5531